Antidyskinetic effects of risperidone on animal models of tardive dyskinesia in mice.
The effects of risperidone, an atypical neuroleptic, were investigated on two animal models of tardive dyskinesia (TD). The repeated administration of reserpine (1.0mg/kg) or haloperidol (2.0mg/kg) induces orofacial movements in mice, which are very similar to those observed in humans presenting TD. The effects of acute or repeated treatment with several doses of risperidone (0.1; 0.5; 2.0 or 4.0) on the expression and development of orofacial movements in reserpine- and haloperidol-treated male mice were investigated. The results showed that risperidone per se did not induce the development of orofacial movements. In addition, this drug was able to attenuate the expression and the development of reserpine-as well as haloperidol-induced orofacial movements. These results are in line with several clinical studies that suggest not only a lower incidence of TD in schizophrenic patients treated with risperidone, but also an antidyskinetic effect of this drug in patients previously treated with classical neuroleptics.
Departamento de Farmacologia, UNIFESP, Rua Botucatu, 862-Ed Leal Prado, São Paulo, SP, CEP 04023-062, Brazil.
R C
RC
Carvalho
R H
RH
Silva
V C
VC
Abílio
P N
PN
Barbosa
R
R
Frussa-Filho
D000284:Administration, Oral; D000818:Animals; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy*; D006220:Haloperidol / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D011897:Random Allocation; D012110:Reserpine / Q000008:administration & dosage / Q000009:adverse effects; D018967:Risperidone / Q000627:therapeutic use*
D014150:Antipsychotic Agents; D012110:Reserpine; D006220:Haloperidol; D018967:Risperidone